Atara Biotherapeutics Inc (NASDAQ:ATRA) CFO John Mcgrath sold 37,000 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $24.35, for a total transaction of $900,950.00. Following the sale, the chief financial officer now owns 93,154 shares of the company’s stock, valued at $2,268,299.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

John Mcgrath also recently made the following trade(s):

  • On Saturday, December 29th, John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $640,000.00.
  • On Friday, December 29th, John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $640,000.00.

Atara Biotherapeutics Inc (ATRA) opened at $28.25 on Monday. The firm has a market cap of $1,062.08, a price-to-earnings ratio of -8.14 and a beta of 1.27. Atara Biotherapeutics Inc has a 52 week low of $11.80 and a 52 week high of $30.40.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.05). analysts forecast that Atara Biotherapeutics Inc will post -4 EPS for the current fiscal year.

Several research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a research note on Wednesday, January 3rd. ValuEngine upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Jefferies Group restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. Finally, Goldman Sachs Group restated a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $26.00.

A number of institutional investors and hedge funds have recently bought and sold shares of ATRA. SG Americas Securities LLC acquired a new stake in Atara Biotherapeutics in the third quarter valued at $142,000. Voya Investment Management LLC raised its holdings in Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,651 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Atara Biotherapeutics in the third quarter valued at $170,000. State of Wisconsin Investment Board acquired a new stake in Atara Biotherapeutics in the second quarter valued at $252,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 1,369 shares in the last quarter. 69.67% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Atara Biotherapeutics Inc (ATRA) CFO Sells 37,000 Shares of Stock” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/insider-selling-atara-biotherapeutics-inc-atra-cfo-sells-37000-shares-of-stock/1807781.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.